New York, USA – November 27, 2020 – Stem cells are non-specialized cells that can be divided into totipotent stem cells, pluripotent stem cells, and multipotent stem cells according to their development level and differentiation ability. In 2006, Shinya Yamanaka discovered the induced pluripotent stem cells (iPSCs) that can eliminate ethical controversy of stem cells and can be generated from the patient’s own cells. Creative Biolabs, as a pioneer in the field of biotechnology CRO, masters the frontier technologies and is fully competent to support stem cell research for global customers in the pharmaceutical, medical, and institutional industry.
The services are basically divided into two streams, one for basic research on stem cells and the other for the development of stem cell therapy.
Creative Biolabs supports the fundamental research projects about induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC). It is worth mentioning that regarding the newly-developing cell therapy tool-organoid, a variety of platforms have been developed for organ development, including cerebral organoid, gastric organoid, and thyroid organoid, which are developed based upon the featured 3D bioprint technology. Furthermore, the stem cell editing techniques deepen the research on stem cell therapy on a genetic level, covering clustered regularly interspaced short palindromic repeat (CRISPR), transcription activator-like effector nuclease (TALEN), and recombinant DNA technology.
Stem Cell Therapy Development
Creative Biolabs can develop stem cell-based therapeutics that are disease-specific and is capable of providing not only iPSC derived immune cell therapy and iPSC derived stem cell therapy services, but also the stem cell facilitated drug discovery (drug screening, toxicity and efficacy analysis, target identification, etc.).
In addition to the above-mentioned services, Creative Biolabs has established disease models with the exclusive STEMODTM disease model platform to help understand the etiology and progression of diverse diseases involving the cardiovascular system, nervous system, and ocular system.
In recent years, basic and clinical researches of stem cells are under rapid development. To date, more than 3,000 clinical trials involving the use of adult stem cells, and 262 phase III clinical trials and above have been documented at the International Clinical Trials Registry Platform (ICTRP), of which the indications cover neurological diseases, cardiovascular diseases, diabetes, blood diseases, and cancer. However, many challenges still need to be resolved before stem cells can be used in cell therapy. Creative Biolabs can be a reliable partner to support the corresponding research cases.
More details can be found at https://www.creative-biolabs.com/stem-cell-therapy.
About Creative Biolabs
Creative Biolabs keeps pace with the most up-to-date technologies, handling the projects from global customers who are working on the development of novel therapeutics. After years of exploration and accumulation, a comprehensive system of stem cell therapy development has been established, which is operated by a group of P.h.D level scientists. Dozens of successful cases and regular customers prove the strengths of Creative Biolabs.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States